ARL4AP1

Across TCGA pan-cancer cohorts, ARL4AP1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ARL4AP1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARL4AP1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARL4AP1 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

CCRCC, LSCC, and PDAC are the cancer types where ARL4AP1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL4AP1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	+1.400	<.001	12	view →
LSCC	Male	II,III,IV	−1.597	<.001	9	view →
PDAC	Male	All	+1.127	<.001	9	view →
LUAD	Female	III,IV	−0.975	<.001	9	view →
COAD	Male	II,III,IV	−0.316	<.001	6	view →
OV	All	All	−1.455	.001	2	view →
HNSC	All	All	+0.239	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ARL4AP1–CCRCC

Open the CCRCC breakdown →